Profile

Change your cover photo
Change your cover photo
This user account status is Approved

This user has not added any information to their profile yet.

Kent
Bernard
Fordham Law School

An Adjunct Professor at Fordham University School of Law, Kent Bernard brings a unique perspective to antitrust, innovation and the impact of antitrust on healthcare R&D, topics on which he has practiced, spoken and written.

For over 30 years Mr. Bernard held a series of increasingly responsible in-house legal positions, retiring at the end of 2007 as Vice President & Assistant General Counsel of Pfizer Inc. and Deputy Managing Partner of the Pfizer Legal Division.

Mr. Bernard is a 1972 graduate of Colgate University, and a magna cum Laude 1975 graduate of the University of Pennsylvania Law School where he was an Articles Editor of the Law Review. He began his career in Philadelphia as an attorney in private practice. He then went in-house, and in 1980, joined the Legal Division at Pfizer. In January 2010 he joined the faculty at Fordham.

POST DATE
U.S. Antitrust Under The Trump Administration - A Fearless And Perhaps Accurate Prediction
2017-02-15
Private Equity Meets Antitrust…Complications Ensue
2018-01-22
Is Full Transatlantic Competition Law Convergence Realistic, or Even Desirable?
2015-12-14
The Affordable Care Act Efficiencies Defense in Section 7 Cases: FTC v. St. Luke’s and Antitrust Unicorns
2015-04-27
Patient Outcomes vs. Competition: Squaring the Circle in FTC v. St. Lukes
2014-09-26
When Does Interpretation Become Rewriting? The FTC Runs With the Actavis Decision
2013-09-26
U.S. Antitrust Enforcement in 2013: Where Are We Going, and Why?
2013-01-14
A Trip Around the Cartel Victims Remedy Buffet
2011-11-16
Innovation Market Theory and Practice: An Analysis and Proposal for Reform
2011-05-17
The Intel Cases—Legal Convergence or Leaps of Faith?
2011-01-06
U.S. Antitrust 2025: How Have We Handled The Bulletproof Cartels?
2010-12-16
The AstraZeneca Decision in the General Court: Some Basic Observations and a Few Interesting Questions
2010-09-29
The Intel Cases—Legal Convergence or Leaps of Faith?
2010-03-01
Some Thoughts on Article 82 Jurisprudence—If the Government Always Wins, Should Private Litigants Win As Well?
2009-08-11
Solving the Wrong Problem—The Preliminary Report on the EC Pharmaceutical Sector Inquiry: What Have We Really Learned?
2009-02-24
The 2008 EC Sector Inquiry Regarding Pharmaceuticals: What Does It Mean from a Research-Based Company Perspective?
2008-11-11
The EC Sector Inquiry Regarding Pharmaceuticals: Some Thoughts from a U.S. Perspective
2008-02-04
Private Damages Actions: A U.S. Perspective on Importing U.S. Damages Actions to the EU
2007-10-29